Virus Vectors Articles & Analysis
19 news found
Furthermore, the company engages in the creation of Virus-like Drug Conjugates (VDCs), which employ virus-like particles as delivery vectors. ...
What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. ...
ByNuvonis
This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. Currently, demand for AAV vectors is rising with more than 550 adeno ...
The preclinical data highlight our 2-vector approach with intramuscular administration as optimal based on immune ...
ASC618 is designed to deliver a shortened, but optimized version of the gene to liver cells, which is expected to work better than the full version. It is carried in a harmless vector, called adeno-associated virus variant 8 (AAV8), that the company derived from a naturally occurring virus. ...
It belongs to the newly created genus Henipavirus and is closely related to Hendra virus and Cedar virus. The Henipavirus family is pleomorphic, which means they come in a variety of shapes, typically 40 to 600 nm in diameter. ...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a ...
(Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD). ...
“Our new facility will help to close that gap by establishing state-of-the-art, modular virus production cleanrooms integrated with the latest vector technologies to maximize speed, flexibility and efficiency throughout our clients’ product development ...
The most promising route that is currently available uses AAV capsids, protein shells derived from the naturally benign human Adeno-associated Virus (AAV), as a vector to carry the healthy copy of the gene to the diseased organ or tissue. ...
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ...
(Nasdaq: BIIB, Cambridge, Mass., USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. ...
About Catalent Cell & Gene Therapy With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. ...
The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform. ...
” PsiOxus’ proprietary T-SIGn® platform uses the enadenotucirev oncolytic virus as a vector to deliver combinations of therapeutic transgenes to carcinomas to fight cancer. ...
Many people throughout the U.S. are familiar with West Nile virus or the more recent advent of the Zika virus," said John Neberz, Business Manager, Vector Division at Central Life Sciences. ...
The antigen is combined with Imaxio’s pro-immunogenic technology IMX313, designed to increase immune responses, and two viral vectors, which are virus carriers modified to be harmless but which can transport the vaccine elements into the body’s cells. One of those is a proprietary viral vector from Okairos (acquired by GSK in 2014). ...
The project summary is as follows: Project #676: Biological Characterization of a Serotype 1 Marek’s Disease Virus-vectored Bi-valent Vaccine for Infectious Laryngotracheitis and Marek’s Disease. ...
Researchers at the University of Western Australia conducted a review of existing literature, and found that the research gaps include a lack of climate change-scenario modelling for diseases caused by plant viruses, and little information on the effects of drought, flooding and heat waves on plant virus diseases. In addition, there is little or no research on the impacts of ...